Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen (OKG-0303) for Acute Infectious Conjunctivitis
Plano, Texas--(Newsfile Corp. - October 6, 2026) - Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, the Company's Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute infectious conjunctivitis. To view the f
Biotechnologies, Pharmaceutique
2026-10-06 9:28 AM EDT | Okogen
Telescope Innovations to Attend the 2026 Cantech Investment Conference in Toronto
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDLs"), and enabling technologies and services for the global pharmaceutical and high-value chemical industries, today announced that members of its leadership team will be in Toronto on October 7 and 8, 2026, including attendance at the Can
Technologies, Produits chimiques, Pharmaceutique
2026-10-06 8:00 AM EDT | Telescope Innovations Corp.
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bi
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-10-06 7:00 AM EDT | Phio Pharmaceuticals Corp.
Telescope Innovations Reports 60% Revenue Growth in Preliminary Unaudited Fiscal Year 2026 Results
Vancouver, British Columbia--(Newsfile Corp. - October 5, 2026) - Telescope Innovations Corp. (CSE: TELI), (OTCQB: TELIF), (FSE: J4U), ("Telescope" or the "Company"), a leading developer of Physical AI systems, including Self-Driving Laboratories ("SDL"), enabling technologies, and services for the global pharmaceutical and chemical industries, today reported 60% growth in gross revenue for fiscal 2026, with revenue reaching C$9.3 million, compared with C$5.8 million in f
Technologies, Produits chimiques, Pharmaceutique
2026-10-05 8:00 AM EDT | Telescope Innovations Corp.
Extendicare Announces Timing of 2026 Third Quarter Results and Conference Call
Markham, Ontario--(Newsfile Corp. - October 5, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced today that it plans to release its financial results for the third quarter of 2026 after market close on Thursday, November 5, 2026. A conference call hosted by Michael Guerriere, President and Chief Executive Officer and David Bacon, Executive Vice President and Chief Financial Officer, will be held on Friday, November 6, 2026, at 11:30 a.m. (EST) to discuss the
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-10-05 8:00 AM EDT | Extendicare Inc.
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
Highlights M3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply. Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.
Biotechnologies, Pharmaceutique
2026-10-05 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - October 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that it has accepted the invitation to present at the National Investment Banking Association's (NIBA) 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida. Robert Bitterman, President and Chief Executive Offic
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-10-05 7:00 AM EDT | Phio Pharmaceuticals Corp.
TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking
Toronto, Ontario--(Newsfile Corp. - October 5, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology company transforming the storage, protection and management of temperature-sensitive medications, is pleased to announce that its VIVI Cap Smart™ platform now supports connectivity with Apple Health and Google Fit, advancing the Company's strategy to make injectable medication use visible within leading health and w
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-10-05 3:05 AM EDT | TempraMed Technologies Ltd.
Voyageur Pharmaceuticals Announces Completion of Shares for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - October 2, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that, further to the Company's news release dated September 24, 2026, the Company has completed its previously announced shares for debt settlement, in settlement of outstanding indebtedness in the aggregate amount o
Pharmaceutique, Mines et métaux
2026-10-02 4:29 PM EDT | Voyageur Pharmaceuticals Ltd.
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
Highlights PharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service. Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutic
Biotechnologies, Pharmaceutique
2026-10-01 8:00 AM EDT | PharmaTher Holdings Ltd.
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to announce its participation in the 17th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California. World ADC San Diego is a leading global foru
Biotechnologies, Pharmaceutique, Santé
2026-10-01 3:15 AM EDT | Defence Therapeutics Inc.
TempraMed Technologies Ltd. Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), is pleased to announce that, further to its September 23, 2026 and September 28, 2026 news releases, it has closed its non-brokered private placement (the "Offering") of unsecured convertible debentures of the Company (each, a "Convertible Debenture") and units (each, a "Unit"). The Company issued $600,000 of principal amount of C
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-30 6:00 PM EDT | TempraMed Technologies Ltd.
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 29, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, today announced that its upcoming Annual General Meeting ("AGM"), originally scheduled for October 14, 2026, has been rescheduled and reclassified as an Annual General and Special Meeting ("AGSM"). The rescheduled meeti
2026-09-29 5:59 PM EDT | BetterLife Pharma Inc.
Appili Therapeutics Announces Transfer to NEX
Halifax, Nova Scotia--(Newsfile Corp. - September 29, 2026) - Appili Therapeutics Inc. (TSX: APLI) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases, announces that it has applied to voluntarily delist its Class A common shares (the "Common Shares") from the Toronto Stock Exchange (the "TSX") and transfer its listing to the NEX Board of the TSX Venture Exchange (the "NEX") as a resu
Biotechnologies, Pharmaceutique, industries.supplementary-medicine.name
2026-09-29 8:30 AM EDT | Appili Therapeutics Inc.
KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception
Key Highlights Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-09-29 7:30 AM EDT | KALA Bio Inc.
BioHarvest Sciences Announces Share Repurchase Program
British Columbia and Rehovot, Israel--(Newsfile Corp. - September 29, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a Botanical Synthesis company developing and manufacturing proprietary plant-based compositions for customers, partners and its own portfolio, announced today that its Board of Directors has authorized a share repurchase program, structured in acc
Biotechnologies, Pharmaceutique, Santé
2026-09-29 7:00 AM EDT | BioHarvest Sciences Inc.
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - September 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is very pleased to announce the appointment of Sherry Aulin to its Board of Directors. Ms. Aulin will also serve as a member of the Company's Audit Committee. Sherry Aulin is a f
Biotechnologies, Pharmaceutique, Santé
2026-09-29 3:15 AM EDT | Defence Therapeutics Inc.
TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
Highlights: LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ throughout Cyprus, subject to a definitive agreement. Proposed exclusivity is conditional on minimum annual purchase obligations, with combined purchases required to increase by at least 20% year over year to maintain exclusivity. Transfer pricing and the first-year minimum combined unit commitment will be nego
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-29 3:05 AM EDT | TempraMed Technologies Ltd.
TempraMed Announces Upsize to Offering
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-brokered private placement (the "Offering") previously announced on Wednesday, September 23, 2026. The Upsized Offering wil
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:49 PM EDT | TempraMed Technologies Ltd.
PreveCeutical Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 28, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce a non-brokered private placement (the "Offering") of up to 20,000,000 units (each, a "Unit") in the capital of the Company at a price of $0.03 per Unit for gross proceeds of up to $600,000. Each Unit consists of one (1) common share of the Company (each, a "Shar
Biotechnologies, Pharmaceutique, Santé
2026-09-28 5:00 PM EDT | PreveCeutical Medical Inc.